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Abstract
Background: A number of studies have suggested that the non-antimicrobial actions of macrolide antibiotics may be valuable
in treating patients with cystic fibrosis. The use of long-term macrolide antibiotics for the management of CF patients colonised
by Pseudomonas aeruginosa and progressive pulmonary disease was introduced into our clinic in 1997. A retrospective study
was undertaken to assess of the impact of this therapy. Methods: Twenty patients with progressive pulmonary disease ()10% fall
in FEV over 12 months despite optimising conventional therapy) were commenced on Azithromycin, 250 mg daily during a 21-1
month period. At the time of assessment they had remained on therapy for a mean of 0.9 years. Changes in lung function, weight,
body mass index (BMI) and frequency of pulmonary exacerbations were assessed. A group of 20 patients with stable lung
function and matched as far as possible for age and sex was identified for comparison. Results: Pulmonary function increased
significantly in the Azithromycin group with FEV1% predicted increasing from a mean of 50.2–59.1% (Ps0.001) while FVC%
predicted increase from 64.5 to 76.1% (Ps0.002). There was small but non-significant fall in lung function in the comparison
group. Body mass index increased by a mean of 1.1 in the Azithromycin group but remained unchanged in the comparison group.
The number of pulmonary exacerbations requiring intravenous antibiotics declined by 48.3% in macrolide treated subjects
compared to the pre-treatment period (P-0.025); frequency of exacerbations in the control group was unchanged. Conclusion:
Long-term Azithromycin treatment in patients with progressive deterioration in lung function appears to have led to an
improvement in pulmonary function, increased body mass index and decreased the frequency of pulmonary exacerbations requiring
intravenous antibiotics.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
Keywords: Cystic fibrosis; Macrolide antibiotics; Pulmonary function
1. Introduction
Progressive pulmonary damage, frequently associated
with chronic endobronchial infection by Staphylococcus
aureus and Pseudomonas aeruginosa, is the major cause
of morbidity and mortality in cystic fibrosis (CF). There
are many factors contributing to this progressive lung
damage including the release of inflammatory mediators
and free proteases from neutrophils (PMN) and exo-
products released by P. aeruginosa w1,2x.
Diffuse pan-bronchiolitis w3,4x is a chronic respiratory
disease of unknown aetiology that is relatively common
in Japan. It is also characterised by chronic inflammation
and infection in small airways with progressive pulmo-
nary damage, eventually resulting in respiratory failure
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and death. Chronic Pseudomonas aeruginosa infection
is common in patients with this disease. Bronchial
lavage reveals increased numbers of neutrophils and
these cells have been implicated in the causation of the
progressive lung disease. Traditionally, the disease was
treated with oral steroids and antibiotics. However, the
introduction of long-term erythromycin (200 mg tds)
therapy in the 1980s led to an increase in 10-year
survival from 12.4 to 90% w5x. Investigators have sug-
gested that this effect is due to anti-inflammatory prop-
erties of the antibiotic rather than any anti-microbial
effect w3–7x. This suggestion is supported by studies
showing improvement accompanied by a fall in IL-8,
neutrophil derived elastase and PMN numbers in bron-
choalveolar lavage fluid w6x.
A number of antibiotics have non-antimicrobial
actions that may be of value in conditions characterised
by chronic endobronchial infection w6x. These actions
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could explain clinical improvement seen in patients
colonised by organisms that are apparently resistant to
specific antibiotic groups. A pilot study demonstrated
that low dose erythromycin administered for 1 month
led to a reduction in IL-8 and neutrophil elastase levels
in the sputum of CF patients w8x. More recent clinical
studies have suggested that the introduction of low dose
macrolide antibiotics may have a beneficial therapeutic
effects in non-CF bronchiectasis and cystic fibrosis w9–
11x.
On the basis of these reports we reviewed the impact
of the introduction of once daily Azithromycin in CF
patients with aggressive chronic endobronchial infection.
In particular we assessed the effect of this intervention
on lung function, pulmonary exacerbations and nutrition.
2. Methods
During the period July 1997 to March 1999 a total of
20 CF patients colonised by Pseudomonas aeruginosa
and progressive pulmonary disease ()10% fall in
FEV over 12 months) despite conventional therapy1
were commenced on long-term Azithromycin therapy.
Subjects were identified from a clinic population of 160
CF patients attending the Sheffield Cystic Fibrosis Cen-
tre. Diagnosis was confirmed by genotype analysis,
sweat test (Na )60 mmolyl) and typical clinical pres-q
entation. All patients were colonised by Pseudomonas
aeruginosa defined as at least three positive bacteriolog-
ical cultures over a 6-month period. They received the
macrolide antibiotic, Azithromycin 250 mg daily, for a
minimum period of 3 months.
Data on 20 patients with stable lung function (-5%
change in FEV and FVC) and Shwachman score over1
the previous 12 months was obtained for comparison.
These patients were all colonised by Pseudomonas
aeruginosa and matched as far as possible for age, sex
and lung function. Data were obtained from matched
time periods. Two patients in each group were also
infected with B. cepacia.
The primary end-point of the study was FEV %1
predicted since it is acknowledged as the closest predic-
tor of morbidity and mortality w12x. Secondary outcome
measures included FVC%, weight gain, body mass index
(BMI), sputum microbiology and infective exacerba-
tions. Clinical status, sputum culture and weight were
evaluated on a monthly basis. Lung function was mon-
itored on a Vitalograph 2120 spirometer and results
expressed according to ageyheight matched standards.
The number of pulmonary exacerbations was noted in
both groups and compared to the pre-trial period. All
standard CF treatments were continued for both groups.
Results were analysed by Student’s t-test test with a
value of P-0.05 taken to indicate statistical signifi-
cance. The change in pulmonary exacerbation frequency
within groups was analysed using the Wilcoxon Rank
sum test.
3. Results
The median age at the start of Azithromycin treatment
was 18.6 years. The median age of the comparison
group was 18.8 years. Fifteen of the 20 patients in each
group were male. Azithromycin treated patients com-
pleted a mean of 0.9"0.5 years therapy. One subject,
excluded from the analysis, developed abdominal pain
after 2 weeks, which resolved when the drug was
discontinued.
Pulmonary function improved significantly in those
patients treated with Azithromycin. Their FEV1% pre-
dicted increased from a mean of 50.2% prior to intro-
duction of treatment to 59.1% (Ps0.001) while FVC%
predicted increase from 64.5 to 76.1% (Ps0.002). In
the comparison group no such improvement was
observed. A small but non-significant fall in FEV1%
predicted from a mean of 58.7 to 57.2% (P)0.3) and
FVC% predicted 74.1 vs. 73.2% (P)0.5) was observed
in these subjects.
The frequency of pulmonary exacerbations requiring
intravenous antibiotics declined in the Azithromycin
treatment group by 48.3% (P-0.025). In the compari-
son groups there was no significant change in intrave-
nous antibiotic use over time with a reduction of 3.5%
(P)0.5) being observed. Macrolide treated patients
gained, on average, significantly more weight than
controls, (3.9 kg vs. 1.3 kg, Ps0.040). A corresponding
increase in BMI was noted in the macrolide treated
group (1.1 vs. 0.1, P-0.05).
Sputum microbiology was unchanged at the end of
the treatment period although one individual in the
treatment group colonised by S. aureus eradicated this
organism. Atypical mycobacteria were sought but were
not isolated in any patient.
4. Discussion
This review of our experience would support the
suggestion that long-term macrolide therapy with Azith-
romycin is associated with a significant improvement in
lung function and a reduction in intravenous antibiotic
use in CF patients colonised by Pseudomonas aerugi-
nosa. The significant improvement in lung function after
commencing Azithromycin is similar to that reported in
two small studies involving paediatric patients w10,11x.
The overall improvement in lung function in Azithro-
mycin treated patients contrasts with essentially static
lung function in the comparison group and the expected
decline in FEV and FVC that might be anticipated1
from reviewing the results of large CF population studies
w13x. Since completing this review the suggestion that
the long-term use of macrolide antibiotics maybe bene-
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ficial in the treatment of cystic fibrosis has been further
strengthened by the publication of a randomised trial
suggesting that Azithromycin improved a number of
parameters including quality of life and reduced the rate
of decline in lung function w15x.
Our experience would also suggest that the use of
Azithromycin is associated with an increase in mean
body weight and BMI. BMI is considered a good marker
of nutritional status, which, in turn, predicts survival
w12x. The combination of poor weight and pulmonary
function combine to predict a worse prognosis w16x. The
increase in weight gain and BMI in macrolide treated
patients may reflect enhanced intestinal motility and
improved nutrient absorption. An alternative and perhaps
more likely explanation is that the improvement in BMI
resulted from reduced calorie demand as a result of
improvements in the patient’s pulmonary status.
The observed improvements are unlikely to reflect an
antimicrobial effect as the macrolides have MICs)128
ugyml against most strains of P. aeruginosa and thus
not bactericidal at therapeutic concentrations w7x.
Macrolides have been shown to disrupt the formation of
Pseudomonal biofilms w4x, diminish Pseudomonas aeru-
ginosa alginate expression w14x, reduce the production
of bacterial virulence factors in vitro and alter PMN
activity w4,7,14x. These antipseudomonal effects occur
at sub-MIC ranges but it is at present unknown whether
they account for clinical efficacy w14x.
Effective gene transfection fully restoring ion trans-
port and function remains an elusive goal in CF w17x.
Therefore, alternative treatments are being sought, espe-
cially for those with established lung disease. Clinicians
have started to use macrolides as an adjunct to other
therapies based on anecdotal reports of efficacy. This
open retrospective study provides further support for the
suggestion that macrolide antibiotics may be of value in
CF patients colonised by Pseudomonas aeruginosa
whose clinical status is deteriorating despite optimising
conventional therapy.
References
w1x Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet
1993;341:1065–9.
w2x Zach MS. Lung disease in cystic fibrosis—an updated concept.
Pediatric Pulmonol 1990;8:188–202.
w3x Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East
meets West. Thorax 1994;49:531–2.
w4x Koyama H, Geddes DM. Erythromycin and diffuse panbron-
chiolitis. Thorax 1997;52:915–8.
w5x Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, et al. Long
term effect of erythromycin activity in patients with chronic
Pseudomonas aeruginosa infection. Thorax 1995;50:1246–52.
w6x Black PN. Anti-inflammatory effects of macrolide antibiotics.
Eur Resp J 1997;10:971–2.
w7x Saiman L. The Use of Macrolide Antibiotics in patients with
Cystic Fibrosis. 22nd European CF Conference Berlin. 1999.
(p. 43).
w8x Everard ML, Sly P, Brennan S, Ryan G. Macrolide antibiotics
in diffuse panbronchiolitis and in cystic fibrosis. Eur Resp J
1997;10:2926.
w9x Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS. A
pilot study of low dose erythromycin in bronchiectasis. Eur
Resp J 1999;13:361–4.
w10x Jaffe A, Francis J, Rosenthal M, Bush A. Long-term Azithro-
mycin may improve lung function in children with cystic
fibrosis. Lancet 1998;351:420.
w11x Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term
Azithromycin in children with cystic fibrosis: a randomised,
placebo-controlled crossover trial. Lancet 2002;360:978–84.
w12x Kerem E, Reisman J, Corey M, Canny G, Levison H. Prediction
of mortality in patients with Cystic Fibrosis. N Engl J Med
1992;326:1187–91.
w13x Corey M, Edwards L, Levison H, Knowles M. Longitudinal
analysis of pulmonary function in patients with cystic fibrosis.
J Ped 1997;131:809–14.
w14x Hoiby N. Pseudomonas in Cystic Fibrosis: past, present, future.
The Fourth Joseph Levy Memorial Lecture, Berlin, June. 1998.
w15x Wolter J, Seeney S, Bell S, Bowler S, Mansel P, McCormack
J. Effect of long term treatment with Azithromycin on disease
parameters in cystic fibrosis: a randomised trial. Thorax
2002;57:212–7.
w16x Elborn JS, Bell SC. Nutrition and survival in cystic fibrosis.
Thorax 1996;51:971–2.
w17x Boucher RC. Status of gene therapy for cystic fibrosis lung
disease. J Clin Inv 1999;103:441–5.
